289 related articles for article (PubMed ID: 26024479)
1. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.
van der Schans J; Kotsopoulos N; Hoekstra PJ; Hak E; Postma MJ
PLoS One; 2015; 10(5):e0127237. PubMed ID: 26024479
[TBL] [Abstract][Full Text] [Related]
2. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
[TBL] [Abstract][Full Text] [Related]
3. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
[TBL] [Abstract][Full Text] [Related]
4. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
5. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
6. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
7. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
8. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Gormez V; Avery B; Mann H
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
[TBL] [Abstract][Full Text] [Related]
9. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Wigal SB; Gupta S; Heverin E; Starr HL
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
[TBL] [Abstract][Full Text] [Related]
11. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
Coghill D; Banaschewski T; Zuddas A; Pelaz A; Gagliano A; Doepfner M
BMC Psychiatry; 2013 Sep; 13():237. PubMed ID: 24074240
[TBL] [Abstract][Full Text] [Related]
12. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
[TBL] [Abstract][Full Text] [Related]
14. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
[TBL] [Abstract][Full Text] [Related]
15. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
Gau SS; Shen HY; Soong WT; Gau CS
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
[TBL] [Abstract][Full Text] [Related]
19. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
Heger S; Trott GE; Meusers M; Schulz E; Rothenberger A; Rettig K; Medori R; Schreiner A; Remschmidt H;
Z Kinder Jugendpsychiatr Psychother; 2006 Jul; 34(4):257-65. PubMed ID: 16927568
[TBL] [Abstract][Full Text] [Related]
20. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
